|
US6828415B2
(en)
*
|
1993-02-19 |
2004-12-07 |
Zentaris Gmbh |
Oligopeptide lyophilisate, their preparation and use
|
|
ES2234325T3
(es)
|
1998-12-15 |
2005-06-16 |
Takeda Pharmaceutical Company Limited |
Procedimiento para producir poliesteres biodegradables.
|
|
CA2378714A1
(en)
|
1999-07-15 |
2001-01-25 |
Takeda Chemical Industries, Ltd. |
Sustained release compositions, methods for producing the same and uses thereof
|
|
WO2002002144A1
(fr)
|
2000-07-05 |
2002-01-10 |
Takeda Chemical Industries, Ltd. |
Preparations medicinales pour le traitement des maladies dependant des hormones sexuelles
|
|
WO2002012369A1
(en)
|
2000-08-07 |
2002-02-14 |
Wako Pure Chemical Industries, Ltd. |
Lactic acid polymer and process for producing the same
|
|
DE10040700A1
(de)
*
|
2000-08-17 |
2002-02-28 |
Asta Medica Ag |
Salze von biologisch aktiven Peptiden, ihre Herstellung und Verwendung
|
|
WO2002043766A1
(en)
*
|
2000-11-29 |
2002-06-06 |
Takeda Chemical Industries, Ltd. |
Medicinal compositions and process for producing the same
|
|
WO2002047722A1
(en)
*
|
2000-12-15 |
2002-06-20 |
Takeda Chemical Industries, Ltd. |
Medicinal compositions of nonpeptidyl gonadotropin-releasing hormone agonist or antagonist, process for producing the same and use thereof
|
|
EP1374855A1
(en)
*
|
2001-03-30 |
2004-01-02 |
Takeda Chemical Industries, Ltd. |
Medicinal solutions
|
|
US20040235748A1
(en)
*
|
2001-04-25 |
2004-11-25 |
Yasutaka Igari |
Agents for preventing postoperative recurrence of premenopausal breast cancer
|
|
TWI225416B
(en)
|
2001-06-29 |
2004-12-21 |
Takeda Chemical Industries Ltd |
Sustained-release composition and process for producing the same
|
|
AR034641A1
(es)
*
|
2001-06-29 |
2004-03-03 |
Takeda Pharmaceutical |
Composicion de liberacion controlada y metodo para producirla
|
|
CA2458452C
(en)
*
|
2001-08-10 |
2011-04-19 |
Takeda Chemical Industries, Ltd. |
Gnrh agonist combination drugs
|
|
CA2463358C
(fr)
*
|
2001-10-10 |
2012-03-13 |
Pierre Fabre Medicament |
Microspheres biodegradables a liberation prolongee et leur procede de preparation
|
|
US7812044B2
(en)
|
2001-11-13 |
2010-10-12 |
Takeda Pharmaceutical Company Limited |
Anticancer agents
|
|
CN1620285A
(zh)
*
|
2001-12-26 |
2005-05-25 |
武田药品工业株式会社 |
新微球和其生产方法
|
|
US7674232B2
(en)
|
2002-04-19 |
2010-03-09 |
Pelikan Technologies, Inc. |
Method and apparatus for penetrating tissue
|
|
US7175642B2
(en)
|
2002-04-19 |
2007-02-13 |
Pelikan Technologies, Inc. |
Methods and apparatus for lancet actuation
|
|
CN1662260B
(zh)
*
|
2002-06-25 |
2010-04-28 |
武田药品工业株式会社 |
缓释组合物的制备方法
|
|
MXPA05002594A
(es)
*
|
2002-09-11 |
2005-05-27 |
Fresenius Kabi Gmbh |
Derivados de polipeptidos con hidroxialquilalmidon, especialmente derivados de eritropoyetina con hidroxialquilalmidon.
|
|
AU2003266581A1
(en)
*
|
2002-09-24 |
2004-04-19 |
Asahi Kasei Chemicals Corporation |
Glycolic acid copolymer and method for production thereof
|
|
US6962006B2
(en)
*
|
2002-12-19 |
2005-11-08 |
Acusphere, Inc. |
Methods and apparatus for making particles using spray dryer and in-line jet mill
|
|
CN101410174B
(zh)
*
|
2003-04-10 |
2011-04-06 |
Pr药品有限公司 |
一种用于生产基于乳化的微观粒子的方法
|
|
US20070207211A1
(en)
*
|
2003-04-10 |
2007-09-06 |
Pr Pharmaceuticals, Inc. |
Emulsion-based microparticles and methods for the production thereof
|
|
CA2532302C
(en)
*
|
2003-07-15 |
2016-12-20 |
Pr Pharmaceuticals, Inc. |
Method for the preparation of controlled release formulations
|
|
AU2004259209A1
(en)
|
2003-07-23 |
2005-02-03 |
Pr Pharmaceuticals, Inc. |
Controlled release compositions
|
|
US20070276024A1
(en)
*
|
2003-10-09 |
2007-11-29 |
Inverseon , Inc. |
Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists
|
|
EP1677778A2
(en)
*
|
2003-10-09 |
2006-07-12 |
Inverseon, Inc. |
Method of treating airway diseases with beta-adrenergic inverse agonists
|
|
TW200529890A
(en)
*
|
2004-02-10 |
2005-09-16 |
Takeda Pharmaceutical |
Sustained-release preparations
|
|
TW200613012A
(en)
*
|
2004-07-02 |
2006-05-01 |
Takeda Pharmaceuticals Co |
Sustained-release composition, process for producing the same and use of the same
|
|
US7528175B2
(en)
*
|
2004-10-08 |
2009-05-05 |
Inverseon, Inc. |
Method of treating airway diseases with beta-adrenergic inverse agonists
|
|
US8222257B2
(en)
|
2005-04-01 |
2012-07-17 |
The Regents Of The University Of California |
Phosphono-pent-2-en-1-yl nucleosides and analogs
|
|
WO2006130217A2
(en)
*
|
2005-04-01 |
2006-12-07 |
The Regents Of The University Of California |
Substituted phosphate esters of nucleoside phosphonates
|
|
US20060222716A1
(en)
*
|
2005-04-01 |
2006-10-05 |
Joseph Schwarz |
Colloidal solid lipid vehicle for pharmaceutical use
|
|
ATE382337T1
(de)
|
2005-04-28 |
2008-01-15 |
Nipro Corp |
Bioabsorbierbare pharmazeutische zusammensetzung enthaltend einen plga-copolymer
|
|
US20070027107A1
(en)
*
|
2005-07-29 |
2007-02-01 |
Curt Hendrix |
Compositions and methods for treating estrogen-dependent diseases and conditions
|
|
US20070190127A1
(en)
|
2005-12-30 |
2007-08-16 |
Mingdong Zhou |
Extended release of neuregulin for improved cardiac function
|
|
MX2008011844A
(es)
*
|
2006-03-13 |
2008-10-02 |
Encysive Pharmaceuticals Inc |
Formulaciones de sitaxsentano de sodio.
|
|
JP2009530284A
(ja)
*
|
2006-03-13 |
2009-08-27 |
エンサイシブ・ファーマシューティカルズ・インコーポレイテッド |
拡張期心不全を治療するための方法と組成物
|
|
MX2008011633A
(es)
*
|
2006-03-13 |
2008-12-16 |
Activx Biosciences Inc |
Aminoquinolonas como inhibidores de gsk-3.
|
|
US20080026061A1
(en)
*
|
2006-06-22 |
2008-01-31 |
Reichwein John F |
Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
|
|
PT2066662E
(pt)
|
2006-09-21 |
2013-02-13 |
Kyorin Seiyaku Kk |
Inibidores de serina-hidrolase
|
|
US20100137421A1
(en)
*
|
2006-11-08 |
2010-06-03 |
Emmanuel Theodorakis |
Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
|
|
GEP20125597B
(en)
|
2006-12-18 |
2012-08-10 |
Takeda Pharmaceutical |
Sustained-release composition and production method thereof
|
|
US7892776B2
(en)
|
2007-05-04 |
2011-02-22 |
The Regents Of The University Of California |
Screening assay to identify modulators of protein kinase A
|
|
RU2343908C1
(ru)
*
|
2007-09-05 |
2009-01-20 |
Руслан Дмитриевич Илюк |
Средство для профилактики и лечения алкоголизма и способ его применения
|
|
US8389514B2
(en)
*
|
2007-09-11 |
2013-03-05 |
Kyorin Pharmaceutical Co., Ltd. |
Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors
|
|
JP5373799B2
(ja)
|
2007-09-12 |
2013-12-18 |
杏林製薬株式会社 |
Gsk−3阻害剤としてのスピロ環式アミノキノロン
|
|
US20090298882A1
(en)
*
|
2008-05-13 |
2009-12-03 |
Muller George W |
Thioxoisoindoline compounds and compositions comprising and methods of using the same
|
|
CN105601619A
(zh)
|
2009-02-27 |
2016-05-25 |
埃姆比特生物科学公司 |
调控jak激酶的喹唑啉衍生物和其使用方法
|
|
US8071591B2
(en)
|
2009-03-11 |
2011-12-06 |
Kyorin Pharmaceutical Co., Ltd. |
7-cycloalkylaminoquinolones as GSK-3 inhibitors
|
|
MX2012001974A
(es)
|
2009-08-19 |
2012-04-11 |
Ambit Biosciences Corp |
Compuestos de biarilo y metodos de uso de los mismos.
|
|
WO2011069002A1
(en)
|
2009-12-02 |
2011-06-09 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
|
US8710092B2
(en)
*
|
2009-12-23 |
2014-04-29 |
Map Pharmaceuticals, Inc. |
Substituted indolo 4,3 FG quinolines useful for treating migraine
|
|
US9296722B2
(en)
|
2010-05-27 |
2016-03-29 |
Ambit Biosciences Corporation |
Azolyl urea compounds and methods of use thereof
|
|
WO2011150201A2
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl amide compounds and methods of use thereof
|
|
MX2013002384A
(es)
|
2010-09-01 |
2013-07-05 |
Ambit Biosciences Corp |
Compuestos quinazolina y metodos para utilizarlos.
|
|
CN103380237A
(zh)
*
|
2010-12-15 |
2013-10-30 |
3M创新有限公司 |
可降解的纤维
|
|
CN103732611B
(zh)
|
2011-01-10 |
2016-06-01 |
伊沃恩有限公司 |
β-肾上腺素能反向激动剂用于戒烟的用途
|
|
AR082266A1
(es)
*
|
2011-05-13 |
2012-11-28 |
Univ Nac Del Litoral |
Microparticula inyectable de liberacion controlada
|
|
US8604035B2
(en)
|
2011-06-23 |
2013-12-10 |
Map Pharmaceuticals, Inc. |
Fluoroergoline analogs
|
|
KR102066297B1
(ko)
|
2011-10-14 |
2020-01-14 |
암비트 바이오사이언시즈 코포레이션 |
헤테로사이클릭 화합물 및 이의 유형 3 수용체 티로신 키나아제의 조절인자로서의 용도
|
|
AU2012355982A1
(en)
|
2011-12-19 |
2014-07-10 |
Map Pharmaceuticals, Inc. |
Novel iso-ergoline derivatives
|
|
EP2793583A4
(en)
|
2011-12-21 |
2015-08-12 |
Map Pharmaceuticals Inc |
NOVEL NEUROMODULATORY CONNECTIONS
|
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
|
EP2934143A4
(en)
|
2012-12-21 |
2016-06-15 |
Map Pharmaceuticals Inc |
NOVEL DERIVATIVES OF METHYSERGIDE
|
|
SG11201601341QA
(en)
|
2013-08-30 |
2016-03-30 |
Ambit Biosciences Corp |
Biaryl acetamide compounds and methods of use thereof
|
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
|
TW201618783A
(zh)
|
2014-08-07 |
2016-06-01 |
艾森塔製藥公司 |
以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
|
|
RU2723559C2
(ru)
|
2014-09-12 |
2020-06-16 |
Тобира Терапьютикс, Инк. |
Комбинированная терапия с применением препарата ценикривирок для лечения фиброза
|
|
EP3209658A1
(en)
|
2014-10-24 |
2017-08-30 |
Biogen MA Inc. |
Diterpenoid derivatives and methods of use thereof
|
|
EP3247357A4
(en)
|
2015-01-20 |
2018-07-11 |
Xoc Pharmaceuticals, Inc |
Isoergoline compounds and uses thereof
|
|
CN107428745A
(zh)
|
2015-01-20 |
2017-12-01 |
Xoc制药股份有限公司 |
麦角灵化合物及其用途
|
|
PT3640345T
(pt)
|
2015-08-17 |
2021-12-29 |
Kura Oncology Inc |
Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase
|
|
EP4455145A3
(en)
|
2015-12-02 |
2025-03-12 |
Astraea Therapeutics, LLC |
Piperidinyl nociceptin receptor compounds
|
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
|
MX395029B
(es)
|
2015-12-29 |
2025-03-24 |
Galderma Sa |
Metodo para desacetilacion de biopolimeros.
|
|
EP3399981B1
(en)
|
2016-01-08 |
2023-08-02 |
Celgene Corporation |
Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
|
|
WO2017120422A1
(en)
|
2016-01-08 |
2017-07-13 |
Celgene Corporation |
Antiproliferative compounds, and their pharmaceutical compositions and uses
|
|
WO2017180794A1
(en)
|
2016-04-13 |
2017-10-19 |
Skyline Antiinfectives, Inc. |
Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams
|
|
WO2017184968A1
(en)
|
2016-04-22 |
2017-10-26 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
|
EP3534885B1
(en)
|
2016-11-03 |
2021-01-20 |
Kura Oncology, Inc. |
Farnesyltransferase inhibitors for use in treating cancer
|
|
WO2018089692A1
(en)
|
2016-11-09 |
2018-05-17 |
Phloronol, Inc. |
Eckol derivatives, methods of synthesis and uses thereof
|
|
TWI693074B
(zh)
|
2017-02-21 |
2020-05-11 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症之方法
|
|
US10137121B2
(en)
|
2017-02-21 |
2018-11-27 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
|
WO2018223065A1
(en)
|
2017-06-01 |
2018-12-06 |
Xoc Pharmaceuticals, Inc. |
Ergoline derivatives for use in medicine
|
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2019032489A1
(en)
|
2017-08-07 |
2019-02-14 |
Kura Oncology, Inc. |
METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS
|
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
|
CN113286591A
(zh)
|
2018-11-01 |
2021-08-20 |
库拉肿瘤学公司 |
用法尼基转移酶抑制剂治疗癌症的方法
|
|
US12391705B2
(en)
|
2018-12-19 |
2025-08-19 |
Shy Therapeutics, Llc |
Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
|
AU2019403379A1
(en)
|
2018-12-21 |
2021-07-15 |
Kura Oncology, Inc. |
Therapies for squamous cell carcinomas
|
|
TWI839461B
(zh)
|
2019-02-06 |
2024-04-21 |
美商戴斯阿爾法股份有限公司 |
Il-17a調節物及其用途
|
|
US20220142983A1
(en)
|
2019-03-01 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2020190604A1
(en)
|
2019-03-15 |
2020-09-24 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
|
SG11202110472WA
(en)
|
2019-03-29 |
2021-10-28 |
Kura Oncology Inc |
Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
|
|
WO2020205387A1
(en)
|
2019-04-01 |
2020-10-08 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2020223583A1
(en)
|
2019-05-02 |
2020-11-05 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
|
CA3154608A1
(en)
|
2019-09-16 |
2021-03-25 |
Dice Alpha, Inc. |
Il-17a modulators and uses thereof
|
|
WO2021242970A1
(en)
|
2020-05-29 |
2021-12-02 |
Boulder Bioscience Llc |
Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
|
|
US20230227466A1
(en)
|
2020-06-18 |
2023-07-20 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
|
WO2022006228A1
(en)
|
2020-06-30 |
2022-01-06 |
Prosetta Biosciences, Inc. |
Isoquinoline derivatives, methods of synthesis and uses thereof
|
|
US20240309015A1
(en)
|
2021-01-27 |
2024-09-19 |
Shy Therapeutics, Llc |
Methods for the Treatment of Fibrotic Disease
|
|
US20240124483A1
(en)
|
2021-01-27 |
2024-04-18 |
Shy Therapeutics, Llc |
Methods for the Treatment of Fibrotic Disease
|
|
MX2023010545A
(es)
|
2021-03-10 |
2023-11-24 |
Dice Molecules Sv Inc |
Inhibidores de integrinas alfa v beta 6 y alfa v beta 1 y usos de los mismos.
|
|
EP4326721A1
(en)
|
2021-04-22 |
2024-02-28 |
Protego Biopharma, Inc. |
Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
|
|
WO2022251533A1
(en)
|
2021-05-27 |
2022-12-01 |
Protego Biopharma, Inc. |
Heteroaryl diamide ire1/xbp1s activators
|
|
CA3236150A1
(en)
|
2021-10-22 |
2023-04-27 |
Prosetta Biosciences, Inc. |
Novel host-targeted pan-respiratory antiviral small molecule therapeutics
|
|
KR102709458B1
(ko)
*
|
2021-11-23 |
2024-09-23 |
한국화학연구원 |
서방출 클로니딘 미립구형 주사제 및 그의 제조방법
|
|
WO2023102378A1
(en)
|
2021-11-30 |
2023-06-08 |
Kura Oncology, Inc. |
Macrocyclic compounds having farnesyltransferase inhibitory activity
|
|
US11932665B2
(en)
|
2022-01-03 |
2024-03-19 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
|
EP4433040A4
(en)
|
2022-01-03 |
2025-11-12 |
Lilac Therapeutics Inc |
ACYCLIC THIOL PRODRUGS
|
|
EP4484415A4
(en)
*
|
2022-02-22 |
2025-10-01 |
Shanghai Yonsun Biotechnology Co Ltd |
MEDICINAL SALT OF CARIPRAZINE AND CRYSTALLINE FORM THEREOF, PHARMACEUTICAL COMPOSITION, PREPARATION METHOD AND USE THEREOF
|
|
CA3253352A1
(en)
|
2022-03-02 |
2023-09-07 |
Mitopower, Inc. |
NEW PROMEDICINAL PRODUCTS DERIVED FROM NICOTINIC ACID AND RIBOSE
|
|
CA3254863A1
(en)
|
2022-03-30 |
2023-10-05 |
Biomarin Pharmaceutical Inc. |
DYSTROPHIN EXON-SKIPPING OLIGONUCLEOTIDES
|
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
|
WO2023201282A1
(en)
|
2022-04-14 |
2023-10-19 |
Bristol-Myers Squibb Company |
Novel gspt1 compounds and methods of use of the novel compounds
|
|
JP2025513822A
(ja)
|
2022-04-15 |
2025-04-30 |
セルジーン コーポレーション |
薬物に対するリンパ腫の応答性を予測する方法及びリンパ腫を治療する方法
|
|
US20230416741A1
(en)
|
2022-05-05 |
2023-12-28 |
Biomarin Pharmaceutical Inc. |
Method of treating duchenne muscular dystrophy
|
|
KR20250099113A
(ko)
|
2022-09-09 |
2025-07-01 |
이노보 테라퓨틱스 인코포레이티드 |
CK1α 및 DUAL CK1α/GSPT1 분해 화합물
|
|
EP4593826A1
(en)
|
2022-09-30 |
2025-08-06 |
Boulder Bioscience LLC |
Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury
|
|
US20240174673A1
(en)
|
2022-10-26 |
2024-05-30 |
Protego Biopharma, Inc. |
Spirocycle Containing Pyridine Compounds
|
|
WO2024092040A1
(en)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Spirocycle containing bicyclic heteroaryl compounds
|
|
WO2024092037A1
(en)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Spirocycle containing pyridone compounds
|
|
EP4626864A1
(en)
|
2022-11-30 |
2025-10-08 |
Protego Biopharma, Inc. |
Linear heteroaryl diamide ire1/xbp1s activators
|
|
WO2024118810A1
(en)
|
2022-11-30 |
2024-06-06 |
Protego Biopharma, Inc. |
Cyclic pyrazole diamide ire1/xbp1s activators
|
|
WO2024226471A2
(en)
|
2023-04-24 |
2024-10-31 |
Biomarin Pharmaceutical Inc. |
Compositions and methods for treating stxbp1 disorders
|
|
TW202448485A
(zh)
|
2023-05-05 |
2024-12-16 |
美商拜奧馬林製藥公司 |
肌萎縮蛋白外顯子跳躍寡核苷酸
|
|
WO2025063888A1
(en)
|
2023-09-19 |
2025-03-27 |
Kancure Pte. Ltd. |
Survivin-targeted compounds
|
|
US20250122182A1
(en)
|
2023-09-27 |
2025-04-17 |
Isosterix, Inc. |
MYST Inhibitors
|
|
WO2025085416A1
(en)
|
2023-10-16 |
2025-04-24 |
Bristol-Myers Squibb Company |
Gspt1 compounds and methods of use of the compounds
|
|
GB2636969A
(en)
|
2023-11-24 |
2025-07-09 |
Ontrack Therapeutics Ltd |
Novel crystalline salt forms
|
|
WO2025147691A1
(en)
|
2024-01-04 |
2025-07-10 |
Innovo Therapeutics, Inc. |
Compositions and methods for degrading aryl hydrocarbon receptor nuclear translocator protein
|
|
WO2025179161A1
(en)
|
2024-02-21 |
2025-08-28 |
Innovo Therapeutics, Inc. |
Protein degrading compounds
|
|
WO2025255341A1
(en)
|
2024-06-05 |
2025-12-11 |
Protego Biopharma, Inc. |
Tetrahydrofuranyl ire1/xbp1s activators
|